E-Health Literacy and Health Seeking Behavior in the Elderly

December 10, 2024 updated by: Zeynep Sacikara, Necmettin Erbakan University

The Effect of Educational Intervention on Digital Health Service Use in the Elderly on E-Health Literacy and Health Seeking Behavior: Randomized Controlled Study

The purpose of this clinical trial is to determine the effect of an educational intervention on the use of digital health services for elderly individuals on e-health literacy and health seeking behavior.

The main questions it aims to answer are:

H 0 : There is no difference in terms of the total score of the e-health literacy scale.

H 0 : There is no difference in terms of the total score of the health seeking behavior scale.

The control group will continue their routine life. The researchers will conduct a 4-week intervention for the intervention group participants.

Technology Use Basic Information Training, MHRS and e-pulse Systems Usage Training Health literacy, mobile health application usage training Counseling Applications will be made at the end of the training.

Study Overview

Status

Status

Indicates the current recruitment status or the expanded access status.
Completed

Conditions

Conditions

The disease, disorder, syndrome, illness, or injury that is being studied. On ClinicalTrials.gov, conditions may also include other health-related issues, such as lifespan, quality of life, and health risks.

Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.

Detailed Description

Electronic health (eHealth) is the use of information and communication technology in support of health and health-related areas and is increasingly integrated into health resources and service delivery (WHO, 2019). The World Health Organization (WHO) also recognizes that digital technologies have the potential to accelerate the achievement of the Sustainable Development Goals by improving health services (WHO, 2021). However, not everyone has sufficient access or skills to use digital technology to benefit from the benefits of eHealth. This situation cannot be ignored, especially for the elderly, who are a vulnerable group (Chang et al., 2021). Elderly health and reducing health inequalities are important issues among the Sustainable Development Goals 2030 (UNDP, 2023). In order to minimize inequalities, it is very important for the individual to adapt to the innovations of the age and develop technology use skills. (Akyazı, 2018; Tuna Uysal, 2020).

The sample size was determined by Power analysis. The sample was calculated as 29 elderly individuals for each group with a power of 90%, with an effect size of 0.88 in an experimental study (Xie 2011). Considering the 10% loss probability for the study group, the sample was determined as 32 for each group (experimental and control). Before randomization, elderly individuals who meet the inclusion criteria will be given general information about the study, their informed consent will be obtained for participation in the study, and a pre-test will be administered. Then, the block randomization method will be used for randomization, and opaque envelopes will be given by an independent researcher to conceal the assignment.

At the end of the study, the training given to the experimental group will also be given to the control group.

Study Type

Study Type

Describes the nature of a clinical study. Study types include interventional studies (also called clinical trials), observational studies (including patient registries), and expanded access.
Interventional

Enrollment (Actual)

Enrollment

The number of participants in a clinical study. The "anticipated" enrollment is the target number of participants that the researchers need for the study.
64

Phase

Phase

The stage of a clinical trial studying a drug or biological product, based on definitions developed by the U.S. Food and Drug Administration (FDA). The phase is based on the study's objective, the number of participants, and other characteristics. There are five phases: Early Phase 1 (formerly listed as Phase 0), Phase 1, Phase 2, Phase 3, and Phase 4. Not Applicable is used to describe trials without FDA-defined phases, including trials of devices or behavioral interventions.
  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Contact

The name and contact information for the person who can answer enrollment questions for a clinical study. Each location where the study is being conducted may also have a specific contact, who may be better able to answer those questions.

Study Contact Backup

Study Locations

  • Turkey
      • Konya, Turkey
        • Necmettin Erbakan Üniversitesi

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Eligibility Criteria

The key requirements that people who want to participate in a clinical study must meet or the characteristics they must have. Eligibility criteria consist of both inclusion criteria (which are required for a person to participate in the study) and exclusion criteria (which prevent a person from participating). Types of eligibility criteria include whether a study accepts healthy volunteers, has age or age group requirements, or is limited by sex.

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

At least literate Having a smart phone Elderly individuals aged 60 and over Having internet access at home or at work

Exclusion Criteria:

Illiterate Not having a smart phone Individuals under the age of 60 Not having internet access at home or at work

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Supportive Care
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Single

Arms and Interventions

Participant Group / Arm

Participant Group / Arm

A group or subgroup of participants in a clinical trial that receives a specific intervention/treatment, or no intervention, according to the trial's protocol.
Intervention / Treatment

Intervention / Treatment

A process or action that is the focus of a clinical study. Interventions include drugs, medical devices, procedures, vaccines, and other products that are either investigational or already available. Interventions can also include noninvasive approaches, such as education or modifying diet and exercise.
No Intervention: Control
Elderly people will continue to receive routine care at the family health center.
Experimental: Intervention
The group in which the intervention was made
Other: Education

The researchers will conduct a 4-week intervention for the intervention group participants.

Technology Use Basic Information Training, MHRS and e-pulse Systems Usage Training Health literacy, mobile health application usage training Counseling Applications will be made at the end of the training

What is the study measuring?

Primary Outcome Measures

Primary Outcome Measures

In a clinical study's protocol, the planned outcome measure that is the most important for evaluating the effect of an intervention/treatment. Most clinical studies have one primary outcome measure, but some have more than one.
Outcome Measure
Measure Description
Time Frame
Total score of e-health literacy scale
Time Frame: pre-test in the first meeting, posttest 4 weeks after registration
There are 8 items measuring users' knowledge, comfort and perceived skills in finding, evaluating and applying electronic health information regarding e-health problems. A 5-point Likert-type measurement is used to evaluate the items. The total score varies between 8 and 40, and higher scores indicate higher perceived skills in finding, evaluating and applying e-health information to make health decisions.
pre-test in the first meeting, posttest 4 weeks after registration

Secondary Outcome Measures

Secondary Outcome Measures

In a clinical study's protocol, a planned outcome measure that is not as important as the primary outcome measure for evaluating the effect of an intervention but is still of interest. Most clinical studies have more than one secondary outcome measure.
Outcome Measure
Measure Description
Time Frame
Health Seeking Behavior Scale total score
Time Frame: pre-test in the first meeting, posttest 4 weeks after registration
The scale consists of 3 dimensions and 12 items: online health seeking (6 items), professional health seeking (3 items), and traditional health seeking (3 items). The items in the scale were measured with 5-point Likert-type scale options (1 = strongly disagree, 5 = strongly agree). The minimum and maximum scores that can be obtained from the scale are 12 and 60, respectively. Higher scores represent better health seeking behavior.
pre-test in the first meeting, posttest 4 weeks after registration

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Sponsor

The organization or person who initiates the study and who has authority and control over the study.
Necmettin Erbakan University

Investigators

Investigators

A researcher involved in a clinical study. Related terms include site principal investigator, site sub-investigator, study chair, study director, and study principal investigator.
  • Principal Investigator: ZEYNEP SAÇIKARA, https://www.erbakan.edu.tr/hemsirelikfak

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

Study Start

The actual date on which the first participant was enrolled in a clinical study. The "anticipated" study start date is the date that the researchers think will be the study start date.
October 7, 2024

Primary Completion (Actual)

Primary Completion

The date on which the last participant in a clinical study was examined or received an intervention to collect final data for the primary outcome measure. Whether the clinical study ended according to the protocol or was terminated does not affect this date. For clinical studies with more than one primary outcome measure with different completion dates, this term refers to the date on which data collection is completed for all the primary outcome measures. The "anticipated" primary completion date is the date that the researchers think will be the primary completion date for the study.
November 5, 2024

Study Completion (Actual)

Study Completion

The date on which the last participant in a clinical study was examined or received an intervention/treatment to collect final data for the primary outcome measures, secondary outcome measures, and adverse events (that is, the last participant's last visit). The "anticipated" study completion date is the date that the researchers think will be the study completion date.
December 10, 2024

Study Registration Dates

First Submitted

First Submitted

The date on which the study sponsor or investigator first submitted a study record to ClinicalTrials.gov. There is typically a delay of a few days between the first submitted date and the record's availability on ClinicalTrials.gov (the first posted date).
October 2, 2024

First Submitted That Met QC Criteria

First Submitted That Met QC Criteria

The date on which the study sponsor or investigator first submits a study record that is consistent with National Library of Medicine (NLM) quality control (QC) review criteria. The sponsor or investigator may need to revise and submit a study record one or more times before NLM's QC review criteria are met. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
October 4, 2024

First Posted (Actual)

First Posted

The date on which the study record was first available on ClinicalTrials.gov after National Library of Medicine (NLM) quality control (QC) review has concluded. There is typically a delay of a few days between the date the study sponsor or investigator submitted the study record and the first posted date.
October 8, 2024

Study Record Updates

Last Update Posted (Estimated)

Last Update Posted

The most recent date on which changes to a study record were made available on ClinicalTrials.gov. There may be a delay between when the changes were submitted to ClinicalTrials.gov by the study's sponsor or investigator (the last update submitted date) and the last update posted date.
December 11, 2024

Last Update Submitted That Met QC Criteria

Last Update Submitted That Met QC Criteria

The most recent date on which the study sponsor or investigator submitted changes to a study record that are consistent with National Library of Medicine (NLM) quality control (QC) review criteria. It is the responsibility of the sponsor or investigator to ensure that the study record is consistent with the NLM QC review criteria.
December 10, 2024

Last Verified

Last Verified

The most recent date on which the study sponsor or investigator confirmed the information about a clinical study on ClinicalTrials.gov as accurate and current. If a study with a recruitment status of recruiting; not yet recruiting; or active, not recruiting has not been confirmed within the past 2 years, the study's recruitment status is shown as unknown.
December 1, 2024

More Information

Terms related to this study

Keywords

Other Study ID Numbers

Other Study ID Numbers

Identifiers or ID numbers other than the NCT number that are assigned to a clinical study by the study's sponsor, funders, or others. These numbers may include unique identifiers from other trial registries and National Institutes of Health grant numbers.
  • 16979

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Cookie Settings

We use cookies to ensure that we give you the best experience on our website. For more details carefully read our Privacy and Cookies Policy. ...>>>You can change your preferences or withdraw your consent at any time by deleting the cookies from your website or computer as described in the policy. Please accept it and choose your preferences by ticking the corresponding boxes in the "Manage Settings" section below. Please carefully read our Terms of Service before you proceed with using any part of this website.
«Manage Settings